63 Views | 25 Downloads
David J. Lefer, Ph.D., Cardiovascular Center of Excellence, Louisiana State University Health Science Center, 533 Bolivar Street, Clinical Sciences Research Building, Suite 408, New Orleans, LA 70112, (T) 504-568-2109 (F) 504-568-3247, dlefe1@lsuhsc.edu
Dr. David Lefer serves as scientific consultant for Sulfagenix Inc, a company focusing on developing H2S-based therapy for clinical use. Dr. Lefer also has stock in both NovoMedix and SAJE Pharma, biotech companies that are developing novel therapeutics for cardiovascular diseases. Other authors declare no conflict of interests.
This work was supported by Grants from NIH National Heart, Lung, and Blood Institute (R01 HL146098, R01 HL146514, R01 HL137711) to DJL, (R01 HL151398) to DJL and MX, (R01 HL133167, R35 HL155651) to FNS, American Heart Association Postdoctoral Grant (20POST3520075) to ZL, and (18POST34020143) to TES.
© American Heart Association, Inc. All rights reserved.